Advertisement

The Editor’s Roundtable: Cyclooxygenase-2 Inhibitors and Cardiovascular Risk

  • Author Footnotes
    † Dr. Bresalier is on the advisory board for Merck Research Laboratories, San Diego, California.
    Robert S. Bresalier
    Footnotes
    † Dr. Bresalier is on the advisory board for Merck Research Laboratories, San Diego, California.
    Affiliations
    Professor and Chairman, Department of Gastrointestinal, Medicine and Nutrition, Birdie J and Lydia J Resoft Distinguished Professor in Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Search for articles by this author
  • Author Footnotes
    § Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    Vincent E. Friedewald Jr
    Correspondence
    Corresponding author: Tel: 574-631-7608; fax: 574-631-8209.
    Footnotes
    § Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    Affiliations
    Visiting Professor and Director, New Media Center, University of Notre Dame, Notre, Dame, Indiana
    Search for articles by this author
  • Author Footnotes
    § Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    Robert E. Rakel
    Footnotes
    § Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    Affiliations
    Professor, Department of Family and Community Medicine, Baylor College of Medicine, Houston, Texas
    Search for articles by this author
  • Author Footnotes
    § Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    William C. Roberts
    Footnotes
    § Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
    Affiliations
    Medical Director, Baylor Heart and Vascular Institute, Baylor, University Medical Center, Dallas, Texas; Editor-in-Chief, The American Journal of Cardiology, and Dean, A. Webb Roberts Center for Continuing Medical Education of Baylor Health Care, System, Dallas, Texas
    Search for articles by this author
  • Author Footnotes
    ‡ Dr. Williams receives honoraria for speaking and consulting for Pfizer, Inc., New York, New York. He is on the advisory board and conducts research protocols for Pfizer.
    Gary W. Williams
    Footnotes
    ‡ Dr. Williams receives honoraria for speaking and consulting for Pfizer, Inc., New York, New York. He is on the advisory board and conducts research protocols for Pfizer.
    Affiliations
    Chairman, Department of Medicine, Scripps Clinic, Medical Group; Vice President, Medicine Services and Academic Affairs Scripps Clinic Foundation, La Jolla, California.
    Search for articles by this author
  • Author Footnotes
    † Dr. Bresalier is on the advisory board for Merck Research Laboratories, San Diego, California.
    ‡ Dr. Williams receives honoraria for speaking and consulting for Pfizer, Inc., New York, New York. He is on the advisory board and conducts research protocols for Pfizer.
    § Drs. Friedewald, Rakel and Roberts have no relevant financial relationships to disclose.Conflicts of interest were resolved through peer review.
Published:October 24, 2005DOI:https://doi.org/10.1016/j.amjcard.2005.09.069
      Some studies referred to in this discussion involved research in the use of COX-2 inhibitors for preventing cancer and Alzheimer’s, but the focus of the discussion is on the cardiovascular side effects of these drugs in the context of that research, not on their efficacy for those conditions. This discussion does not explore the efficacy of these drugs for any unlabeled uses, nor are unlabeled uses recommended.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. U.S. Food and Drug Administration (FDA) Alert. Available at: http://www.fda.gov/cder/drug/infopage/celebrex/celebrex-ptsk.htm. Accessed April 7, 2005.

        • Vane J.R.
        Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs.
        Nat New Biol. 1971; 231: 232-235
        • Bombardier C.
        • Laine L.
        • Reicin A.
        • Shapiro D.
        • Burgos-Vargas R.
        • Davis B.
        • Day R.
        • Ferraz M.B.
        • Hawkey C.J.
        • Hochberg M.C.
        • Kvein T.K.
        • Schnitzer T.J.
        Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis.
        N Engl J Med. 2000; 343: 1520-1528
        • Solomon D.H.
        • Schneeweiss S.
        • Glynn R.J.
        • Kiyota Y.
        • Levin R.
        • Mogun H.
        • Avorn J.
        Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
        Circulation. 2004; 109: 2068-2073
        • Ray W.A.
        • Stein C.
        • Daugherty J.
        • Hall K.
        • Arbogast P.G.
        • Griffin M.R.
        COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
        Lancet. 2002; 360: 1071-1073
        • Ray W.A.
        • Stein C.M.
        • Hall K.
        • Daugherty J.R.
        • Griffin M.R.
        Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.
        Lancet. 2002; 359: 118-123
        • Graham D.J.
        • Campen D.
        • Hui R.
        • Spence M.
        • Cheetham C.
        • Levy G.
        • Shoor S.
        • Ray W.A.
        Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs.
        Lancet. 2005; 365: 475-481
        • Johnsen S.P.
        • Larsson H.
        • Tarone R.E.
        • McLaughlin J.K.
        • Nørgård B.
        • Friis S.
        • Sørensen H.T.
        Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs.
        Arch Intern Med. 2005; 165: 978-984
      2. Sudbo J Lee JJ, Lippman SM, Dannenberg AJ, Sagen S, Mork J, Ristimki A, Sudbo A Kildal W, Reith A. Non-steroidal anti-inflammatory drugs, tobacco and the risk of oral cancer. Abstract 4377 presented April 18 at the 96th annual meeting of the American Association for Cancer Research, Anaheim, CA.

        • Bresalier R.S.
        • Sandler R.S.
        • Quan H.
        • Bolognese J.A.
        • Oxenius B.
        • Horgan K.
        • Lines C.
        • Riddell R.
        • Morton D.
        • Lanas A.
        • Konstam M.A.
        • Baron J.A.
        Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
        N Engl J Med. 2005; 352: 1092-1102
        • Juni P.
        • Nartey L.
        • Reichenbach S.
        • Sterchi R.
        • Dieppe P.A.
        • Egger M.
        Risk of cardiovascular events and rofecoxib.
        Lancet. 2004; 364: 2021-2029
        • Solomon D.H.
        • Schneeweiss S.
        • Glynn R.J.
        • Kiyota Y.
        • Levin R.
        • Mogun H.
        • Avorn J.
        Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
        Circulation. 2004; 109: 2068-2073
      3. Merck News Release. Available at: www.merck.com/newsroom/press_releases/product/2004_0930.html. Accessed August 3, 2005.

        • Silverstein F.E.
        • Faich G.
        • Goldstein J.L.
        • Simon L.S.
        • Pincus T.
        • Whelton A.
        • Makuch R.
        • Eisen G.
        • Agrawal N.M.
        • et al.
        Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial.
        JAMA. 2000; 284: 1247-1255
      4. Celecoxib [package insert]. GD Searle LLC, a subsidiary of Pharmacia Corporation, Chicago, Il2002 (August)
        • Solomon S.D.
        • McMurray J.J.
        • Pfeffer M.A.
        • Wittes J.
        • Fowler R.
        • Finn P.
        • Anderson W.F.
        • Zauber A.
        • Hawk E.
        • Bertagnolli M.
        • Adenoma Prevention with Celecoxib (APC) Study Investigators
        Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
        N Engl J Med. 2005; 352: 1071-1080
      5. Levin B. FDA Advisory Board Committee Meeting. February 17, 2005: Gaithersburg, MD.

      6. Clinical Trials Details. Available at: http://www.clinicaltrials.gov/ct/show/NCT00007189?order=1. Accessed August 3, 2005.

        • Martin B.K.
        • Meinert C.L.
        • Breitner J.C.
        • ADAPT Research Group
        Double placebo design in a prevention trial for Alzheimer’s disease.
        Control Clin Trials. 2002; 23: 93-99
      7. NIH Press Release on Suspension. Available at: http://www.nih.gov/news/pr/dec2004/od-20.htm. Accessed August 3, 2005.

      8. NIH Clinical Trials. Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Available at http://www.clinical%20trials.gov/ct/show/NCT00007189?order=1. Accessed August 3, 2005.

        • Nussmeier N.A.
        • Whelton A.A.
        • Brown M.T.
        • Langford R.M.
        • Hoeft A.
        • Parlow J.L.
        • Boyce S.W.
        • Verburg K.M.
        Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery.
        N Engl J Med. 2005; 352: 1081-1091
        • Farkouh M.E.
        • Kirshner H.
        • Harrington R.A.
        • Ruland S.
        • Verheugt F.W.
        • Schnitzer T.J.
        • Burmester G.R.
        • Mysler E.
        • Hochberg M.C.
        • et al.
        Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes.
        Lancet. 2004; 364: 675-684
        • Baron J.A.
        • Cole B.F.
        • Sandler R.S.
        • Haile R.W.
        • Ahnen D.
        • Bresalier R.
        • McKeown-Eyssen G.
        • Summers R.W.
        • Rothstein R.
        • et al.
        A randomized trial of aspirin to prevent colorectal adenomas.
        N Engl J Med. 2003; 348: 891-899
        • Ott E.
        • Nussmeir N.A.
        • Duke P.C.
        • Feneck R.O.
        • Alston R.P.
        • Snabes M.C.
        • Hubbard R.C.
        • Hsu P.H.
        • Saidman L.J.
        • Mangano D.T.
        Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary bypass surgery.
        J Thorac Cardiovasc Surg. 2003; 125: 1481-1492
        • Furberg C.D.
        • Psaty B.M.
        • FitzGerald G.A.
        Parecoxib, valdecoxib, and cardiovascular risk.
        Circulation. 2005; 111: 249
        • Alsalameh S.
        • Burian M.
        • Mahr G.
        • Woodcock B.G.
        • Geisslinger G.
        Review article.
        Aliment Pharmacol Ther. 2003; 17: 489-501
      9. February 16–18, 2005 Joint Meeting with the Arthritis Drug Advisory Committee. Transcript of February 17, 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005–4090T2.htm. Accessed August 3, 2005.

      10. Food and Drug Administration. April 6, 2005. Available at: http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf. Accessed August 3, 2005.

        • Fitzgerald G.A.
        • Patrono C.
        The coxibs, selective inhibitors of cyclooxygenase-2.
        N Engl J Med. 2001; 345: 433-442
        • Fitzgerald G.A.
        Coxibs and cardiovascular disease.
        N Engl J Med. 2004; 351: 1709-1711
        • Cheng Y.
        • Austin S.C.
        • Rocca B.
        • Koller B.H.
        • Coffman T.M.
        • Grosser T.
        • Lawson J.A.
        • FitzGerald G.A.
        Role of prostacyclin in the cardiovascular response to thromboxane A2.
        Science. 2002; 296: 539-541
        • Ridker P.M.
        • Cushman M.
        • Stampfer M.J.
        • Tracy R.P.
        • Hennekens C.H.
        Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
        N Engl J Med. 1997; 336: 973-979
        • Ross R.
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Weyland C.M.
        • Goronzy J.J.
        • Goronzy J.J.
        • Liuzzo G.
        • Kopecky S.L.
        • Holmes D.R.
        • Frye R.L.
        T-cell immunity in acute coronary syndromes.
        Mayo Clin Proc. 2001; 76: 1011-1020
        • Libby P.
        Inflammation in atherosclerosis.
        Nature. 2002; 420: 868-874
        • Chenevard R.
        • Hurlimann D.
        • Bechir M.
        • Enseleit F.
        • Spieker L.
        • Hermann M.
        • Riesen W.
        • Gay S.
        • Gay R.E.
        • Neidart M.
        • et al.
        Selective COX-2 inhibition improves endothelial function in coronary artery disease.
        Circulation. 2003; 107: 405-409
        • Walter M.
        • Jacob R.F.
        • Day C.A.
        • Dahlborg R.
        • Weng Y.
        • Mason R.P.
        Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification.
        Atherosclerosis. 2004; 177: 235-243
        • Chobanian A.V.
        • Bakris G.L.
        • Black H.R.
        • Cushman W.C.
        • Green L.A.
        • Izzo J.L.
        • Jones D.W.
        • Materson B.J.
        • Oparil S.
        • Wright J.T.
        • Roccella E.J.
        Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
        Hypertension. 2003; 42: 1206-1252
        • Whelton A.
        • White W.B.
        • Bello A.E.
        • Puma J.A.
        • Fort J.G.
        Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis.
        Am J Cardiol. 2002; 90: 959-963
      11. MMWR: Comorbidity of high blood pressure and arthritis. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/00001503.htm. Accessed August 3, 2005.

        • Whelton A.
        • Fort J.G.
        • Puma J.A.
        • Normandin D.
        • Bello A.E.
        • Verburg K.M.
        Cyclooxygenase-2-specific inhibitors and cardiorenal function.
        Am J Ther. 2001; 8: 85-95
        • White W.B.
        • Kent J.
        • Taylor A.
        • Verburg K.M.
        • Lefkowich J.B.
        • Whelton A.
        Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.
        Hypertension. 2002; 39: 929-934
        • Sowers J.R.
        • White W.B.
        • Pitt B.
        • Whelton A.
        • Simon L.
        • Winner N.
        • Kivitz A.
        • van Ingen H.
        • Brabant T.
        • Fort J.
        • Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators
        Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure in treated hypertensive patients with osteoarthritis and type-2 diabetes mellitus.
        Arch Intern Med. 2005; 165: 161-168
        • Ridker P.M.
        • Cook N.R.
        • Lee I.-M.
        • Gordon D.
        • Gaziano M.
        • Manson J.E.
        • Hennekens C.H.
        • Buring J.E.
        A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
        N Engl J Med. 2005; 352: 1293-1304
        • Eidelman R.S.
        • Hebert P.R.
        • Weisman S.E.
        • Hennekens C.H.
        An update on aspirin in the primary prevention of cardiovascular disease.
        Arch Intern Med. 2003; 163: 2006-2010
        • Catella-Lawson F.
        • Muredach P.R.
        • Kapoor S.C.
        • Cucchiara A.J.
        • DeMarco S.
        • Tournier B.
        • Vyas S.N.
        • FitzGerald G.A.
        Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.
        N Engl J Med. 2001; 345: 1809-1817
        • MacDonald T.M.
        • Wei L.
        Effect of ibuprofen on cardioprotective effect of aspirin.
        Lancet. 2003; 306: 573-574
        • Lanas A.
        • Bresalier R.S.
        • Sandler R.
        • Bolognese J.
        • Qan H.
        • Oxenius B.
        • Horgan K.
        • Riddell R.
        • Morton D.
        • Baron J.A.
        Upper gastrointestinal events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
        Gastroenterology. 2005; 129: 371
        • Capone M.L.
        • Tacconelli S.
        • Sciulli M.G.
        • Grana M.
        • Ricciotti E.
        • Minuz P.
        • Gregorio P.D.
        • Merciaro G.
        • Patrono C.
        • Patrignani P.
        Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
        Circulation. 2004; 109: 1468-1471
        • Hermann M.
        • Krum H.
        • Ruschitzka F.
        To the heart of the matter.
        Circulation. 2005; 112: 941-945
        • Kelly J.P.
        • Kaufman D.W.
        • Jurgelon J.M.
        • Sheehan J.
        • Koff R.S.
        • Shapiro S.
        Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.
        Lancet. 1996; 348: 1413-1416
        • Rahme E.
        • Barkun A.
        • Toubouti Y.
        • Rochon S.
        • LeLorier J.
        Do proton pump inhibitors (PPI) infer additional gasrointestinal protection in patients given celecoxib?.
        Pharmacoepidemiology and Drug Safety. 2005; 14: S189
        • Laine L.
        • Maller E.S.
        • Yu C.
        • Quan H.
        • Simon T.
        Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition.
        Gastroenterology. 2004; 127: 395-402
        • Graham D.Y.
        • Agrawal N.M.
        • Campbell D.R.
        • Haber M.M.
        • Collis C.
        • nLukasik N.L.
        • Huang B.
        Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs.
        Arch Intern Med. 2002; 162: 169-175
        • Dannenberg A.J.
        • Subbaramaiah K.
        Targeting cyclooygenase-2 in human neoplasia.
        Cancer Cell. 2003; 4: 431-443
        • Steinbach G.
        • Lynch P.M.
        • Phillips R.K.S.
        • Wallace M.H.
        • Hawk E.
        • Gordon G.B.
        • Wakabayashi N.
        • Saunders B.
        • Shen Y.
        • Fujimura T.
        • Su L.K.
        • Levin B.
        The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
        N Engl J Med. 2000; 342: 1946-1952
      12. Celecoxib Treatment for Lung Cancer. Available at: http://www.clinicaltrials.gov/ct/show/NCT00108186?order=1. Accessed August 3, 2005.

        • Johnson A.G.
        • Nguyen T.V.
        • Day R.O.
        Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.
        Ann Intern Med. 1994; 121: 289-300
        • Topol E.J.
        Failing the public health—rofecoxib, Merck, and the FDA.
        N Engl J Med. 2004; 351: 1707-1709
        • Chandrasekharan N.V.
        • Dai H.
        • Roos L.T.
        • Evanson N.K.
        • Tomsik J.
        • Simmon D.L.
        COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs.
        Proc Natl Acad Sci USA. 2002; 99: 13926-13931
        • Perneger T.V.
        • Whelton P.K.
        • Klag M.J.
        Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs.
        N Engl J Med. 1994; 331: 1675-1679
        • Curhan G.C.
        • Knight E.L.
        • Rosner B.
        • Hankinson S.E.
        • Stampfer M.J.
        Lifetime nonnarcotic analgesic use and decline in renal function in women.
        Arch Intern Med. 2004; 164: 1519-1524
        • Forman J.P.
        • Stampfer M.J.
        • Curhan G.C.
        Non-narcotic analgesic dose and risk of incident hypertension in US women.
        Hypertension. 2005; 46: 500-507
        • Garcia Rodriguez L.A.
        • Hernandez-Diaz S.
        Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs.
        Epidemiology. 2001; 12: 570-576
        • Rahme E.
        • Pettitt D.
        • LeLorier J.
        Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population.
        Arthritis Rheum. 2002; 46: 3046-3054
        • Woolf A.D.
        • Zeidler H.
        • Haglund U.
        • Carr A.J.
        • Chaussade S.
        • Cucinotta D.
        • Veale D.J.
        • Martin-Mola E.
        • Arthritis Action Group
        Musculoskeletal pain in Europe.
        Ann Rheum Dis. 2004; 63: 342-347
        • Pincus T.
        • Swearingen C.
        • Cummins P.
        • Callahan L.F.
        Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both drugs in patients with osteoarthritis.
        J Rheumatol. 2000; 27: 1020-1027